Exciton Technologies Receives Approval from China Food and Drug Administration for its Patented Silver Wound Dressing
Exciton Technologies has received approval from the China Food and Drug Administration (CFDA) for Exsalt®, the Company’s line of wound care products, using the antimicrobial properties of silver to prevent bacterial growth and the spread of infections.
The registration process was led by MKS Medicine Technology, a Beijing-based medical device company in conjunction with a distribution agreement signed in 2013. MKS will primarily focus on selling to the burn and chronic wound markets in highly populated areas of southeastern China, including Beijing, Guangdong Province and Shanghai. With more than 90 million diabetics and a growing population of elderly people, the need for effective wound care products is high. CFDA approval expands the global reach for Exciton’s platform Ag Oxysalts™ technology. Sales of Exsalt® dressings could potentially double Exciton’s manufacturing output during the next year.